Skip to content
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
BioTechGrid BioTechGrid
  • Home
  • Biotechnology
  • Medical Technology
  • Research
  • Genetics
  • Press Releases
    • Business Wire
    • GlobeNewswire
    • PRNewswire
  • Contact
  • Home
  • 2026
  • June
  • Page 32
china-sets-framework-for-advanced-therapeutic-development
Posted inGenetics

China Sets Framework for Advanced Therapeutic Development

June 18, 2026
Credit: Liu Liqun / Corbis Documentary / Getty Images China’s Order 818—Regulations on the Administration of Clinical Research and Clinical…
Read More
perseverance,-persistence-key-to-car-t-success,-say-ross-prize-winners-carl-june-and-michel-sadelain
Posted inGenetics

Perseverance, Persistence Key to CAR T Success, Say Ross Prize Winners Carl June and Michel Sadelain

June 18, 2026
The two honorees, Michel Sadelain, PhD, and Carl June, MD, receive their awards during an event to celebrate the 13th…
Read More
helmed-by-sanofi-vet,-bionyra-emerges-with-$165m-and-three-licensed-i&i-assets
Posted inBiotechnology

Helmed by Sanofi vet, Bionyra emerges with $165M and three licensed I&I assets

June 18, 2026
For Bionyra Pharma co-founder and CEO Frédéric Marrache, M.D., Ph.D., “the planets had to align” to pull him out of…
Read More
nirrin-technologies-and-st.-japan-partner-on-next-gen-protein-quantitation-tech
Posted inGenetics

Nirrin Technologies and S.T. Japan Partner on Next-Gen Protein Quantitation Tech

June 18, 2026
Credit: Christoph Burgstedt/Science Photo Library/Getty Images Nirrin Technologies appointed S.T. Japan as its exclusive distribution partner for the TALOSTM protein…
Read More
campfield-harvests-$180m-series-a-to-advance-oral-ibd-drug-licensed-from-newsoara
Posted inBiotechnology

cAMPfield harvests $180M series A to advance oral IBD drug licensed from Newsoara

June 18, 2026
In another biotech born out of China’s “NewCo” model, cAMPfield Therapeutics has launched with a $180 million series A and…
Read More
kardigan-buttons-up-$400m-upsized-ipo-to-power-heart-drugs-toward-phase-3
Posted inBiotechnology

Kardigan buttons up $400M upsized IPO to power heart drugs toward phase 3

June 18, 2026
Kardigan’s IPO haul has come in 14% above expectations, grossing $400 million after the cardiovascular disease biotech upsized the offering and…
Read More
novocure-device-fails-to-improve-brain-cancer-patients’-survival-in-phase-3-test
Posted inMedical Technology

Novocure device fails to improve brain cancer patients’ survival in phase 3 test

June 18, 2026
Novocure’s tumor-treating electric fields device missed its primary endpoint in a late-stage glioblastoma trial.  The Swiss medtech’s product has an…
Read More
biogen-inks-$1b-raythera-buyout-to-bag-preclinical-immunology-assets
Posted inBiotechnology

Biogen inks $1B RayThera buyout to bag preclinical immunology assets

June 18, 2026
Biogen has struck a backloaded, $1 billion deal to buy RayThera, snagging a pipeline of anti-inflammatory drug candidates led by a…
Read More
confined-migration-causes-dna-damage-in-neurons
Posted inBiotechnology

Confined Migration Causes DNA Damage in Neurons

June 18, 2026
In a groundbreaking study published in Nature, researchers have illuminated the subtle yet profound effects of confined cellular migration on…
Read More
multimodal-multitask-ai-transforms-lung-cancer-grading
Posted inBiotechnology

Multimodal Multitask AI Transforms Lung Cancer Grading

June 18, 2026
In a groundbreaking advancement that could revolutionize cancer prognosis and treatment, a team of researchers led by Liu, X., Dai,…
Read More

Posts pagination

Previous page 1 … 30 31 32 33 34 … 120 Next page

Privacy Policy    Terms

Scroll to Top